The aim of this work was to investigate the mechanism of the vasodilatory effect induced by Lcarnitine. Relaxation produced by L-carnitine was studied in rat aortic rings with and without functional endothelium, pre-contracted with phenylephrine by adding cumulative doses of Lcarnitine (10 7 to 10 3 M). The relaxation evoked by L-carnitine reached higher values in aortic rings from spontaneously hypertensive rats than those obtained in arteries from normotensive rats; no relaxation was produced in de-endothelialized arteries. However, in the presence of N G -nitro-Larginine (3¬ 10 5 M, a nitric oxide synthase inhibitor), Ro 68070 (10 4 M, a thromboxane synthetase inhibitor-thromboxane A 2 /prostaglandin H 2 receptor antagonist) or ICI 192605 (10 5 M, a thromboxane A 2 receptor antagonist) the relaxant response to L-carnitine was signi cantly inhibited. These results show that L-carnitine induced endothelium-dependent relaxation in the rat aorta and the mechanism of this relaxation appeared to be mostly mediated by endothelial production of nitric oxide but also could involve prevention of the action of cyclooxygenase endothelial products acting on the thromboxane A 2 /prostaglandin H 2 receptor.
Introduction
l -Carnitine and its derivates have received increasing attention, mainly because of their bene® cial eOE ects on ischaemic tissues (Bartels et al 1995 ; Tatlican et al 1998) , and are being used in a spectrum of diseases including multiple cardiovascular conditions (Arsenian 1997) . Carnitine has useful properties in some cardiovascular pathologies such as heart failure (Mancini et al 1992 ; Sethi et al 1999) , angina pectoris (Bartels et al 1994 ; Mondillo et al 1995) and arrhythmias (Rizzon et al 1989) . In the same way, lcarnitine has been shown to be useful in patients with essential hypertension and diabetes (Digiesi et al 1989) , because it was able to improve the left ventricle function and to induce lowering of some fractions of serum lipids (Digiesi et al 1994) . Therefore, l -carnitine might prevent some cardiovascular alterations by its in¯uence on lipid metabolism (Rauchova! et al 1998) . Despite most published data on carnitine and its derivates being favourable, clinical trials have been relatively scanty and the mechanism by which the function during ischaemia is improved is not fully known. An unknown mechanism of action is implicated in improving the walking capacity in patients with peripheral vascular disease (Brevetti et al 1992) and alternative mechanisms, independent of the classical metabolic pathways, have been proposed to explain the bene® cial eOE ects of these compounds (Fritz et al 1993) .
The objective of this study was to investigate the possible vasoactive eOE ects of lcarnitine in isolated aorta from spontaneously hypertensive rats and to determine the contribution of the endothelium to mediating these vasodilatory eOE ects.
Materials and Methods

Chemical reagents and drugs
l -carnitine, acetylcholine chloride, indometacin, N G -nitrol -arginine (L-NOARG), noradrenaline (norepinephrine) bitartrate, phenylephrine hydrochloride and trans-2phenylcyclopropyl-amine (tranylcypromine) were purchased from Sigma Chemical Co (St Louis, MO). ICI 192,605 was from Tocris (Biogen Cienti® ca S.L. Spain). Ridogrel (Ro-68070) was generously provided by Janssen Pharmaceutical (Beerse, Belgium ). The drugs were dissolved in distilled water, except indometacin and ICI 192,605 which were dissolved in dimethyl sulfoxide (DMSO); stock solutions were prepared at 10 2 m concentration. The ® nal concentration of DMSO in the tissue bath was less than 0.1 % , which was shown to have no eOE ect on the basal tonus of the preparation. All concentrations of the drugs used are expressed as ® nal concentration in the organ chamber.
Animals
Male spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto (WKY) rats, 10± 12 weeks old, weighing 250± 300 g, were housed at 24 2°C with 60 20 % relative humidity, on a 12-h light± dark cycle. Rats were given free access to a diet of standard chow and water. SHR with systolic pressure (SBP) higher than 170 mmHg were used in the experiments. All experiments were performed according to the guidelines for the ethical treatment of animals of the European Union. The rats were killed by cervical dislocation and the aortae were rapidly dissected.
Aortic ring preparation
The descending thoracic aorta was placed in a modi® ed Krebs± Henseleit solution (PSS) containing (mm ): NaCl 118, KCl 4.75, NaHCO 3 25, MgSO 4 1.2, CaCl 2 1.8, KH 2 PO 4 1.2 and glucose 11. After excess fat and connective tissue were removed, the aortae were cut into 2± 3-mm rings. Aortic rings were mounted under a basal tension of 2 g in 20-mL organ baths containing PSS and attached to an isometric transducer (Harvard UF-1);the signal was recorded by a Powerlab data acquisition system (AD-Instruments). The tissue bath was maintained at 37°C and bubbled with a 95 % O 2 ± 5 % CO 2 gas mixture. In some experiments, the endothelium was mechanically removed by gently rubbing the intimal surface. The absence of endothelium was con® rmed by the absence of relaxing eOE ects of acetylcholine (10 6 m ) in aortic rings previously contracted by noradrenaline (norepinephrine) (10 5 m ). Each preparation was allowed to equilibrate for at least 90 min before initiation of experimental procedures, and during this period the incubation medium was changed every 20 min (Alvarez de Sotomayor et al 2001) .
Relaxant effect of L-carnitine
The relaxant eOE ect of l -carnitine was assessed by adding cumulative concentrations of this drug (10 7 to 10 3 m ) to aortic rings precontracted by phenylephrine (3¬ 10 7 m in WKY rats or 10 6 m in SHR). This experiment was carried out in both intact and endothelium-denuded arteries.
To analyse the in¯uence of endothelial factors, vessels were incubated for 30 min with L-NOARG (3¬ 10 5 m , an inhibitor of nitric oxide synthesis), indometacin (10 5 m , to inhibit prostaglandin production), tranylcypromine (10 4 m , a PGI 2 inhibitor), ICI 192,605 (10 5 m , a thromboxane A 2 receptor antagonist) or ridogrel (Ro-68070 ; a thromboxane synthetase inhibitor± thromboxane A 2 }prostaglandin H 2 receptor antagonist) (10 4 m ) which were added to the bath 60 min before the response to phenylephrine was tested. DiOE erent aortic rings were used in each experiment. After incubation, aortae were contracted with phenylephrine (3¬ 10 7 m or 10 6 m ) and when the contractile response was reached, l -carnitine (10 7 to 10 3 m ) was tested by adding cumulative doses every 15 min, in the presence of these diOE erent inhibitors. All the results were expressed as a percentage of the maximal contraction of phenylephrine-induced responses.
Statistical analysis
Results are expressed as percentages from the initial precontraction level and as means s.e.m (n¯6 rats). Eight preparations were studied from a single aorta. Analysis of variance and Tukey' s multiple comparison test were used for statistical analysis. P ! 0.05 values were considered to represent a signi® cant diOE erence. All curves were ® tted by a concentration± response non-linear regression equation.
Results
Relaxation induced by L-carnitine
Addition of l -carnitine (10 7 to 10 3 m ) to aortic rings precontracted with phenylephrine (3¬ 10 7 and 10 6 m for WKY and SHR, respectively) elicited endothelium-dependent relaxation (P ! 0.01) ( Figure 1 ). The maximal re- laxant eOE ect of l -carnitine in intact aortic rings was 36.64 8.3 % and 61.71 7.6 % for WKY and SHR, respectively.
Effect of nitric oxide synthase inhibition
To test whether nitric oxide is involved in the endotheliumdependent relaxation to l -carnitine, the eOE ect of nitric oxide synthase inhibitor L-NOARG (3¬ 10 5 m ) was studied. In these conditions, L-NOARG completely inhibited endothelium-dependent relaxation in aortic rings from normotensive rats. Pre-incubation with L-NOARG also inhibited l -carnitine-induced relaxation in arteries obtained from SHR (P ! 0.01). However, in the SHR aortic rings, at l -carnitine concentrations in the range 10 6 to 10 5 m an L-NOARG-resistant relaxant eOE ect remained (Figure 1 ).
Involvement of prostanoids in the effect of L-carnitine
The presence of the cyclooxygenase inhibitor indometacin (10 5 m ) did not aOE ect endothelium-dependent relaxation in either WKY or SHR aortic rings. When both nitric oxide synthase and cyclooxygenase were blocked together, the L-NOARG-resistant relaxation in SHR aortic rings was inhibited ( Figure 2) . The eOE ects of synthetase inhibitor± thromboxane A 2 } prostaglandin H 2 receptor antagonist Ro 68070 (10 4 m ) and thromboxane A 2 }prostaglandin H 2 receptor antagonist ICI 192,605 (10 5 m ) were also tested. Both Ro 68070 and ICI 192,605 were able to signi® cantly inhibit the endothelial relaxant response to l -carnitine in SHR arteries (Figure 3) . When testing the combination of L-NOARG plus Ro 68070, the results obtained were the same as those observed with L-NOARG plus indometacin.
As shown in Figure 4 , the prostacyclin synthetase inhibitor, tranylcipromine (10 4 m ), did not have any signi® - cant eOE ect on concentration± response curves to l -carnitine. Pre-incubation with tranylcipromine plus L-NOARG did not aOE ects the results obtained with L-NOARG alone.
Discussion
Carnitine has sometimes been bene® cial as a therapeutic agent. Examples include cardiac myopathies and peripheral arterial disease (Ferrari et al 1992) , and improving the walking capacity in patients with peripheral vascular disease (Brevetti et al 1992) . In animal models, l -carnitine and its derivatives have shown some bene® cial eOE ect such as protection against the development of vascular lesions in peripheral arterial insu ciency induced by intra-arterial injection of sodium laurate (Corsico et al 1993) , the prevention of progression of atherosclerotic lesions (Spagnoli et al 1995) and age-dependent rise of plasma total cholesterol, triglycerides and uric acid of SHR (Rauchova! et al 1998) and the reduction in polyploid cells also in SHR (Mauriello et al 1996) . However, the mechanism of action implicated in some of the therapeutic applications of lcarnitine is still unclear. The aim of this study was to investigate the vasodilatory eOE ect of l -carnitine on isolated thoracic aorta from spontaneously hypertensive rats (SHR) and their normotensive genetic control Wistar Kyoto (WKY) rats. The results provide direct evidence of the involvement of endothelium in the concentration-dependent vasorelaxation induced by l -carnitine. Most of this endothelium-dependent eOE ect seems to be mediated by nitric oxide because in the presence of L-NOARG, the inhibitor of nitric oxide synthesis, the relaxation to l -carnitine was signi® cantly diminished compared with that of intact arteries from both WKY rats and SHR. The response of arteries in the presence of L-NOARG was similar to that of denuded arteries. However, SHR aortic rings showed an L-NOARG-resistant relaxant eOE ect in response to low concentrations of l -carnitine, indicating that the production of nitric oxide was involved in mediating the vasodilatory eOE ects of l -carnitine but it did not seem to be the only endothelial factor released by lcarnitine addition. In contrast, the cyclooxygenase inhibitor, indometacin, did not aOE ect the endothelium-dependent response to l -carnitine. However, exposure to indometacin plus L-NOARG resulted in a larger inhibitory eOE ect than L-NOARG alone, abolishing completely the response of intact arteries to l -carnitine, removing the remaining eOE ect. These data led us to think that the vasodilator properties of l -carnitine might involve the participation of vasoactive products from cyclooxygenase, endothelial relaxant or vasoconstrictor factors in addition to nitric oxide.
To verify the nature of endothelial products from the cyclooxygenase possibly involved in the vasodilator properties of l -carnitine, the presence of a prostacyclin synthetase inhibitor did not signi® cantly aOE ect the concentra-tion± response curve. When the same inhibitor was used in addition to L-NOARG, the result was similar to that obtained in the presence of indometacin plus L-NOARG, suggesting that prostaglandin I 2 could be involved, but its eOE ect was only obvious when nitric oxide synthesis was blocked. Incubation with Ro 68070 and ICI 192,605 signi®cantly decreased the sensitivity and maximal relaxation to l -carnitine in arteries from SHR rats. Taken together, these data suggest that l -carnitine could prevent the vasoconstrictor action of cyclooxygenase endothelial products acting on the thromboxane A 2 }prostaglandin H 2 receptor. This observation could help explain how l -carnitine was more eOE ective in relaxing arteries from hypertensive rats than from normotensive rats since the release of this endothelium-dependent contracting factor (EDCF) (including endoperoxides and thromboxane A 2 ) explains the abnormal relaxations (Auch-Schwelk et al 1992) and contractions to acetylcholine (Auch-Schwelk et al 1990) observed in the aorta and small resistance arteries of the SHR. The EDCF released from the hypertensive endothelium interacts chemically with nitric oxide, and both mediators inactivate each other (Ito et al 1991 ; Auch-Schwelk et al 1992) . Such a chemical interaction explains the blunting of endothelium-dependent relaxations, despite a normal ability of the endothelial cells to release endothelium-derived relaxing factors (Vanhoutte 1996) . This larger release of prostaglandin H 2 or thromboxane A 2 in the SHR may result from a greater production (Ge et al 1995) . On the other hand, oxidative stress can accompany hypertension in many models, including the SHR (Wilcox 2002) . It has been shown that hypertension leads to enhanced superoxide production in the vasculature (Kojda et al 1999) . Therefore, we cannot discard the possibility that carnitine might also possess bene® cial eOE ects on superoxide anion production in addition to nitric oxide bioavailability.
Conclusion
This study provides evidence of a vascular relaxation in response to l -carnitine in the aorta of hypertensive rats. The mechanism appeared mostly to be mediated by endothelial production of nitric oxide but also could involve prevention of the action of cyclooxygenase endothelial products acting on TXA 2 }PGH 2 receptors without discarding the possibility that carnitine might also possess bene-® cial eOE ects on superoxide anion production. These ® ndings in relation to endothelial function might help to better understand the bene® cial cardiovascular eOE ects of l -carnitine.
